2025 ISAKOS Biennial Congress ePoster
The ‘French Paradox’ In Australia: How Does The Quadra-C Stem Compare To Other Cemented Stems In The Australian National Joint Replacement Registry?
Christopher J. Wilson, A/Prof, MBChB, MRCS, FRACS, PhD, Adelaide, SA AUSTRALIA
Peter L. Lewis, MBBS, FRACS(Orth), FAOrthA, Adelaide, SA AUSTRALIA
Flinders Medical Centre, Adelaide, SA, AUSTRALIA
FDA Status Cleared
Summary
The Quadra-C Stem performs well with regards revision rates compared to other well performing cemented stems
ePosters will be available shortly before Congress
Abstract
Introduction
The Medacta Quadra C has been in regular use within our department for total hip arthroplasty
(THA) utilising the direct anterior approach (DAA). Local surgical observations have suggested
low initial rates of revision with the ‘French Paradox’ cemented (Quadra-C) stem. The aim of this
study was to use registry data to determine the revision outcome for this stem compared to all
other cemented THA stems used in Australia.
Methods
Data was requested from the AOANJRR, the national joint registry to assess the revision rates
using the Quadra-C hip stem. All patients included had a primary THA performed for the primary
diagnosis of osteoarthritis (OA). Outcomes were compared between the Quadra-C versus the
Exeter stem, the most common hip stem recorded in the AOANJRR and all other cemented THA
stems. Results were expressed as a cumulative percent revision (CPR).
Results
There were 30,641 cemented femoral stem THA with 5,017 performed with the Quadra-C, 14,071
performed Exeter V40, and 11,533 performed with all other cemented stems. The Quadra-C had
a lower CPR than the Exeter stem from 6 months (p=0.003) and also when compared to all other
remaining cemented stems from 6 months onwards (p<0.001).
Conclusions
Current results of the quadra-c stem suggest low revision rates compared to Exeter and all
conventional cemented hip stems within the 14 years of follow-up.